Efficacy Assessment of the Co-Administration of Vancomycin and Metronidazole in Clostridioides difficile -Infected Mice Based on Changes in Intestinal Ecology
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Vancomycin (VAN) and metronidazole (MTR) remain the current drugs of choice for the treatment of non-severe Clostridioides difficile infection (CDI); however, while their co-administration has appeared in clinical treatment, the efficacy varies greatly and the mechanism is unknown. In this study, a CDI mouse model was constructed to evaluate the therapeutic effects of VAN and MTR alone or in combination. For a perspective on the intestinal ecology, 16S rRNA amplicon sequencing and nontargeted metabolomics techniques were used to investigate changes in the fecal microbiota and metabolome of mice under the co-administration treatment. As a result, the survival rate of mice under co-administration was not dramatically different compared to that of single antibiotics, and the former caused intestinal tissue hyperplasia and edema. Co-administration also significantly enhanced the activity of amino acid metabolic pathways represented by phenylalanine, arginine, proline, and histidine, decreased the level of deoxycholic acid (DCA), and downregulated the abundance of beneficial microbes, such as Bifidobacterium and Akkermansia. VAN plays a dominant role in microbiota regulation in co-administration. In addition, co-administration reduced or increased the relative abundance of antibiotic-sensitive bacteria, including beneficial and harmful microbes, without a difference. Taken together, there are some risks associated with the co-administration of VAN and MTR, and this combination mode should be used with caution in CDI treatment.
Abstract
Vancomycin (VAN) and metronidazole (MTR) remain the current drugs of choice for the treatment of non-severe Clostridioides difficile infection (CDI); however, while their co-administration has appeared in clinical treatment, the efficacy varies greatly and the mechanism is unknown. In this study, a CDI mouse model was constructed to evaluate the therapeutic effects of VAN and MTR alone or in combination. For a perspective on the intestinal ecology, 16S rRNA amplicon sequencing and nontargeted metabolomics techniques were used to investigate changes in the fecal microbiota and metabolome of mice under the co-administration treatment. As a result, the survival rate of mice under co-administration was not dramatically different compared to that of single antibiotics, and the former caused intestinal tissue hyperplasia and edema. Co-administration also significantly enhanced the activity of amino acid metabolic pathways represented by phenylalanine, arginine, proline, and histidine, decreased the level of deoxycholic acid (DCA), and downregulated the abundance of beneficial microbes, such as Bifidobacterium and Akkermansia. VAN plays a dominant role in microbiota regulation in co-administration. In addition, co-administration reduced or increased the relative abundance of antibiotic-sensitive bacteria, including beneficial and harmful microbes, without a difference. Taken together, there are some risks associated with the co-administration of VAN and MTR, and this combination mode should be used with caution in CDI treatment.
참고문헌 (41)
- Shen A, "Clostridioides difficile spore formation and germination : new insights and opportunities for intervention", Annu. Rev. Microbiol, 74, pp.545~566 (2020)
- Schnizlein MK, "Capturing the environment of the Clostridioides difficile infection cycle", Nat. Rev. Gastroenterol. Hepatol, 19, pp.508~520 (2022)
- Guh AY, "Clostridioides difficile infection", Ann. Intern. Med, 169, pp.ITC49~ITC64 (2018)
- Beinortas T, "Comparative efficacy of treatments for Clostridium difficile infection : a systematic review and network meta-analysis", Lancet Infect. Dis, 18, pp.1035~1044 (2018)
- Zar FA, "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity", Clin. Infect. Dis, 45, pp.302~307 (2007)
- Tashiro S, "Optimal therapeutic recommendation for Clostridioides difficile infection in pediatric and adolescent populations : a systematic review and meta-analysis", Eur. J. Pediatr, 182, pp.2673~2681 (2023)
- Fitzpatrick F, "How can patients with Clostridioides difficile infection on concomitant antibiotic treatment be best managed?", Lancet Infect. Dis, 22, pp.e336~e340 (2022)
- Wu Y, "A narrative review of Clostridioides difficile infection in China", Anaerobe, 74, pp.102540~ (2022)
- Kim J, "Which is the preferred regimen for non-severe Clostridioides difficile infection in Korea, vancomycin or metronidazole?", Infect. Chemother, 54, pp.213~219 (2022)
- Bass SN, "Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection", J. Hosp. Infect, 85, pp.22~27 (2013)
- Fishbein SRS, "Randomized controlled trial of oral vancomycin treatment in Clostridioides difficile-colonized patients", mSphere, 6, pp.e00936-20~ (2021)
- Lewis BB, "Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole", J. Infect. Dis, 212, pp.1656~1665 (2015)
- Yamaguchi T, "The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin", J. Infect. Chemother, 26, pp.483~491 (2020)
- Bao H, "Oral vancomycin as secondary prophylaxis for Clostridioides difficile infection", Pediatrics, 148, pp.e2020031807~ (2021)
- Zhang K, "Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection", BMC Infect. Dis, 19, pp.51~ (2019)
- Chen X, "A mouse model of Clostridium difficileassociated disease", Gastroenterology, 135, pp.1984~1992 (2008)
- Erikstrup LT, "Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination", BMJ Open Gastroenterol, 2, pp.e000038~ (2015)
- Bokulich NA, "Optimizing taxonomic classification of markergene amplicon sequences with QIIME 2 ' s q2-feature-classifier plugin", Microbiome, 6, pp.90~ (2018)
- Magoc T, "FLASH : fast length adjustment of short reads to improve genome assemblies", Bioinformatics, 27, pp.2957~2963 (2011)
- Callahan BJ, "DADA2 : High-resolution sample inference from Illumina amplicon data", Nat. Methods, 13, pp.581~583 (2016)
- Katoh K, "MAFFT : a novel method for rapid multiple sequence alignment based on fast Fourier transform", Nucleic Acids Res, 30, pp.3059~3066 (2002)
- Price MN, "FastTree : computing large minimum evolution trees with profiles instead of a distance matrix", Mol. Biol. Evol, 26, pp.1641~1650 (2009)
- Shannon CE, "IEEE Xplore Abstract – A mathematical theory of communication", Bell System. Tech. J, 27, pp.379~656 (1948)
- Bray JR, "An ordination of the upland forest communities of southern Wisconsin", Ecol. Monogr, 27, pp.326~349 (1957)
- Ondov BD, "Interactive metagenomic visualization in a Web browser", BMC Bioinformatics, 12, pp.385~ (2011)
- Ramette A, "Multivariate analyses in microbial ecology", FEMS Microbiol. Ecol, 62, pp.142~160 (2007)
- Segata N, "Metagenomic biomarker discovery and explanation", Genome Biol, 12, pp.R60~ (2011)
- Douglas GM, "PICRUSt2 for prediction of metagenome functions", Nat. Biotechnol, 38, pp.685~688 (2020)
- Ng JSY, "Development of an untargeted metabolomics method for the analysis of human faecal samples using Cryptosporidium-infected samples", Mol. Biochem. Parasitol, 185, pp.145~150 (2012)
- Ponnusamy K, "Microbial community and metabolomic comparison of irritable bowel syndrome faeces", J. Med. Microbiol, 60, pp.817~827 (2011)
- Want EJ, "Global metabolic profiling procedures for urine using UPLC–MS", Nat. Protoc, 5, pp.1005~1018 (2010)
- Liu JF, "Interaction tolerance detection test for understanding the killing efficacy of directional antibiotic combinations", mBio, 13, pp.e0000422~ (2022)
- Sandhu BK, "Clostridioides difficile", Trends Microbiol, 26, pp.1049~1050 (2018)
- Konikoff T, "Oscillospira : a central, enigmatic component of the human gut microbiota", Trends Microbiol, 24, pp.523~524 (2016)
- Peng X, "Whole genome sequencing for the risk assessment of probiotic lactic acid bacteria", Crit. Rev. Food Sci. Nutr, 63, pp.11244~11262 (2022)
- Si J, "Revisiting the role of Akkermansia muciniphila as a therapeutic bacterium", Gut Microbes, 14, pp.2078619~ (2022)
- Shin NR, "Proteobacteria : microbial signature of dysbiosis in gut microbiota", Trends Biotechnol, 33, pp.496~503 (2015)
- Rooks MG, "Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission", ISME J, 8, pp.1403~1417 (2014)
- Fletcher JR, "Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota", Nat. Commun, 12, pp.462~ (2021)
- Theriot CM, "Role of microbiota-derived bile acids in enteric infections", Cell, 181, pp.1452~1454 (2020)
- Wilson KH, "Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis", Infect. Immun, 34, pp.626~628 (1981)